GlassScriptPhysician profile
Bryan D Garruto
NPI 1710902911
$1,262.90
in general payments reported to CMS, 2019-2025
19 companies · $264 in 2025
The $264 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2021: $210 · 2022: $135 · 2023: $327 · 2024: $178 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $769.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $362.18 | 2019-2024 | Eylea Hd, Eylea |
| Horizon Therapeutics Plc | $171.15 | 2023 | Tepezza |
| Abbvie INC. | $105.37 | 2022-2023 | |
| Genentech USA, INC. | $93.99 | 2024-2025 | Vabysmo |
| Shire North American Group INC | $65.80 | 2019 | |
| Notal Vision, INC. | $55.53 | 2022 | |
| Dompe US, INC. | $49.91 | 2025 | Oxervate |
| Biotissue Holdings INC. | $48.88 | 2025 | |
| Amgen INC. | $46.29 | 2024-2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $42.02 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $37.09 | 2019-2025 | |
| Kala Pharmaceuticals, INC. | $36.18 | 2021 | |
| Alcon Vision LLC | $35.89 | 2024-2025 | Clareon |
| Harrow Eye, LLC | $25.72 | 2025 | Vevye |
| Bausch & Lomb Americas INC. | $22.72 | 2024 | Xiidra |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $18.12 | 2023 | Tyrvaya |
| Novartis Pharmaceuticals Corporation | $16.88 | 2019 | |
| Thea Pharma INC. | $16.03 | 2023 | |
| Allergan, INC. | $13.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Garruto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.